Ozempic, the brand name for semaglutide manufactured by Novo Nordisk, is currently under legal scrutiny. Jaclyn Bjorklund spearheaded the initial lawsuit, targeting not only Ozempic but also its counterpart Mounjaro (tirzepatide) and Eli Lilly, its manufacturer. However, the lawsuits are still in their infancy, with no global settlements or jury trials in sight.

As of March 2024, there hasn’t been a single Ozempic class-action lawsuit in the U.S. demanding refunds. Instead, attorneys are focusing on personal injury lawsuits related to gastroparesis, ileus, and intestinal blockage or obstruction. Meanwhile, a separate Ozempic patent litigation MDL has seven pending cases.

February 2024

At least 55 lawsuits claiming Ozempic and other GLP-1 RAS class drugs caused severe gastrointestinal injuries were combined into a federal multidistrict litigation in the Eastern District of Pennsylvania. Plaintiff lawyers expected the number could grow to as many as 10,000.

January 2024

The FDA announced it was evaluating reports of hair loss, suicidal thoughts, and aspiration under sedation and anesthesia among people taking Ozempic and similar diabetes and weight loss medications.

December 2023

Judge James Cain, Jr. denied Novo Nordisk’s attempt to dismiss Jaclyn Bjorklund’s case. He did dismiss the express warranty claims but allowed all other claims, including failure to warn, to proceed. Plaintiff lawyers filed a motion to consolidate Ozempic cases in Louisiana District Court.

November 2023

Canadians filed a proposed class action lawsuit in B.C. Supreme Court alleging Novo Nordisk failed to adequately warn prospective patients about potential complications, specifically gastroparesis, linked to Ozempic.

September 2023

The FDA added warnings for intestinal blockage, intestinal obstruction, and ileus to Ozempic’s label. These conditions cause the intestines to stop working properly. Lawyers began accepting claims related to these newly added warnings.

August 2023

Jaclyn Bjorklund became one of the first individuals to file an Ozempic and Mounjaro gastroparesis lawsuit. Summonses to Novo Nordisk and Eli Lilly were issued on Aug. 3. Three months later, on Nov. 3, 2023, Novo Nordisk filed a motion to dismiss Bjorklund’s lawsuit in Louisiana federal court.

July 2023

The American Society of Health-System Pharmacists (ASHP), the largest association of pharmacy professionals in the U.S., advised that Novo Nordisk was facing a shortage of Ozempic and Wegovy, another semaglutide, due to increased demand.

Who Qualifies To File an Ozempic Lawsuit?

• Individuals who took Ozempic for weight loss or any other indication and subsequently experienced gastroparesis may qualify to file a lawsuit.
• Eligibility typically extends to those who suffered severe gastroparesis resulting in vomiting for four weeks or more.
• It’s important to note that individuals who underwent gastric bypass surgery, gastric banding, or gastric sleeve surgery before taking Ozempic may not qualify to file a lawsuit.
• Additionally, individuals being treated for cancer are generally not eligible to pursue Ozempic lawsuits.
• These criteria serve as guidelines, and only an Ozempic lawyer can provide definitive confirmation of qualification. It’s crucial to contact an expert promptly for a free case review to preserve the right to file a lawsuit for potential compensation.
• Depending on the state of residence, individuals may have a limited timeframe to file a claim.

Call Us Today For a Free Case Review!

For individuals who believe they have been injured by Ozempic, immediate action is recommended. Contact our experts at 323-763-8247 today to connect with a reputable law firm specialized in handling Ozempic cases. Our team will facilitate a hassle-free experience in finding the best legal representation for your situation.